Lv11
96 积分 2024-11-22 加入
TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer
10天前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
20天前
已完结
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
20天前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
The Cardiovascular Safety of Antiparkinsonian Drugs-Analysis of Signals in the FDA Adverse Event Report System Database
1个月前
已完结
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
1个月前
已完结
Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study
1个月前
已完结
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)
1个月前
已完结
Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database
1个月前
已完结